Skip to main navigation
Skip to search
Skip to main content
HSC Home
Home
Research units
Profiles
Publications
Sponsored Projects
Core Facilities
Search by expertise, name or affiliation
Response to Pazopanib in Patients With Relapsed Osteosarcoma
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Response to Pazopanib in Patients With Relapsed Osteosarcoma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Pazopanib
100%
Relapsed Osteosarcoma
100%
Osteosarcoma
66%
Chemotherapy
33%
Positive Responses
33%
Tyrosine Kinase Inhibitor
33%
Targeted Therapy
33%
Soft Tissue Sarcoma
33%
Renal Cell Carcinoma
33%
Incidence Rate
33%
Metastatic Disease
33%
Surgery Therapy
33%
Primary Tumor
33%
Surgical Resection
33%
Stable Disease
33%
Gastrointestinal Toxicity
33%
Axial Skeleton
33%
Tumor Necrosis
33%
Medicine and Dentistry
Osteosarcoma
100%
Pazopanib
100%
Disease
33%
Tumor Necrosis
33%
Metastatic Carcinoma
33%
Phosphotransferase Inhibitor
33%
Surgery
33%
Targeted Therapy
33%
Soft Tissue Sarcoma
33%
Primary Tumor
33%
Clear Cell Renal Cell Carcinoma
33%
Gastrointestinal Toxicity
33%
Axial Skeleton
33%
Chemotherapy
33%